Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 1,070 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward Md Kaye sold 1,070 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $30.65, for a total value of $32,795.50. Following the completion of the sale, the director directly owned 51,305 shares in the company, valued at approximately $1,572,498.25. This represents a 2.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $30.58 on Thursday. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The stock has a market capitalization of $1.75 billion, a P/E ratio of 45.53 and a beta of 1.14. The stock has a fifty day moving average of $28.74 and a 200-day moving average of $19.61.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). The business had revenue of $10.63 million during the quarter, compared to the consensus estimate of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. On average, research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Institutional Trading of Stoke Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Generali Investments Management Co LLC bought a new position in Stoke Therapeutics during the 3rd quarter worth $41,000. BNP Paribas Financial Markets raised its position in shares of Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Stoke Therapeutics by 461.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock worth $50,000 after acquiring an additional 3,591 shares during the period. Strs Ohio acquired a new position in shares of Stoke Therapeutics in the third quarter worth approximately $150,000. Finally, Osaic Holdings Inc. boosted its holdings in Stoke Therapeutics by 263.3% in the second quarter. Osaic Holdings Inc. now owns 7,488 shares of the company’s stock valued at $85,000 after acquiring an additional 5,427 shares during the last quarter.

Analysts Set New Price Targets

STOK has been the topic of several research reports. BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Wedbush raised their target price on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Stoke Therapeutics in a report on Monday. JPMorgan Chase & Co. boosted their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research report on Monday, November 3rd. Finally, Needham & Company LLC upped their target price on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, October 10th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $31.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.